Morgellons Research Foundation-Newsletter Dec-`07

https://i0.wp.com/www.ecplanet.com/pic/2007/10/1191344768/morgellons_diffusion_in_the_world.jpg

Morgellons Research Foundationhttps://i2.wp.com/www.post-gazette.com/images4/20060723HO_Morgellons_A_230.jpg
PO Box 357
Guilderland, NY 12084-0357
December 2007 Newsletter
Topics:
1. Labor HHS Bill S. 1710 (Morgellons Funding)
2. SUNY Scanning Electron Microscopy
3. Director of Media and PR
4. New members of the Board of Nursing
Dear MRF Registrants:
1.The Executive Director of the MRF met with staff at U.S. Senator Tom Harkin’s Washington DC office earlier this year. We would like to thank Senator Harkin for adding language regarding additional Morgellons funding to the Labor HHS appropriations Bill S.1710 which was approved by the Senate but vetoed by President Bush. The money which will be used to fund the current (Kaiser Permanente) Morgellons investigation is coming from CDC’s general fund; the vetoed bill would have allowed for additional funding. We are encouraged by the Senate’s attempt to gain additional funding for Morgellons disease and hope that future attempts will be successful.
U.S. Senate Bill 1710: See Morgellons disease on pages 76-77:
http://www.earmarks.omb.gov/resources/tracking_pdfs/pdf
2. Please see SEM (Scanning Electron Microscopy) images generated by Dr Citovsky’s research group at SUNY Stonybrook. We would like to thank Mark Darrah, Research Director of the Morgellons Project in Dr Citovsky’s lab for arranging for the SEM imaging which was done at the Materials Science and Engineering Dept, Stony Brook University. Dr Citovsky’s group, under the direction of Mark Darrah, is continuing to research Morgellons disease and we will share new information as it becomes available to us.
SUNY SEM Images:
http://www.morgellons.com/SUNY%20Images.htm
3. We are pleased to welcome Candice Han, as the new MRF Director of Media and PR. Candice, who has a background in Public Relations, contacted the MRF to volunteer her services. We are most grateful to Candice for this kind and selfless act.
4. We are pleased to welcome two new members to the MRF Board of Nursing:
Barbara Slebodnick, RN and Theresa Lyons, RN.
We would like to thank these new volunteers and everyone who is working together to help end the suffering caused by Morgellons disease.
We wish each of you a joyful and peaceful Holiday season with a Wonderful New Year ahead.
William T. Harvey, M.D., M.P.H., M.S., Chairman
Mary M. Leitao, Executive Director
Douglas Buckner, Ph.D., Associate Director
Janelle Fossen, Secretary
Dale Cowher, CPA, Treasurer
Roy Houchins
Board of Directors
Morgellons Research Foundation

__________________________________________________Morgellons Research Foundation Newsletter


Note: We regret that not everyone on our maillist receives our newsletter. Unfortunately, many newsletters are blocked by SPAM filters and other security features over which we have no control. Please see the instructions on the bottom of this webpage for tips on how to prevent this from happening. We will continue to post our newsletters to our website, so please check this page periodically. Please add “info@mrf-news.com” to your email address book. This will improve the chances of your newsletter not being blocked by SPAM filters.

Older newsletters can be found following the current newsletter.

 

To ensure that you receive our newsletter, please add “info@mrf-news.com” to your email address book.

https://i2.wp.com/www.kvue.com/news/health/stories/M_IMAGE.10af4d01520.93.88.fa.d0.2107b2fc.jpg

SOURCE

Advertisements

Penn study finds hyperbaric oxygen treatments mobilize stem cells

Recovery of injured and diseased tissue the ultimate goal

https://i2.wp.com/medicineworld.org/images/news-blogs/SThomMDPhD.jpg

According to a study to be published in the American Journal of Physiology-Heart and Circulation Physiology, a typical course of hyperbaric oxygen treatments increases by eight-fold the number of stem cells circulating in a patient’s body. Stem cells, also called progenitor cells are crucial to injury repair. The study currently appears on-line and is scheduled for publication in the April 2006 edition of the American Journal. Stem cells exist in the bone marrow of human beings and animals and are capable of changing their nature to become part of many different organs and tissues. In response to injury, these cells move from the bone marrow to the injured sites, where they differentiate into cells that assist in the healing process. The movement, or mobilization, of stem cells can be triggered by a variety of stimuli – including pharmaceutical agents and hyperbaric oxygen treatments. Where as drugs are associated with a host of side effects, hyperbaric oxygen treatments carry a significantly lower risk of such effects.

“This is the safest way clinically to increase stem cell circulation, far safer than any of the pharmaceutical options,” said Stephen Thom, MD, Ph.D., Professor of Emergency Medicine at the University of Pennsylvania School of Medicine and lead author of the study. “This study provides information on the fundamental mechanisms for hyperbaric oxygen and offers a new theoretical therapeutic option for mobilizing stem cells.”

“We reproduced the observations from humans in animals in order to identify the mechanism for the hyperbaric oxygen effect,” added Thom. “We found that hyperbaric oxygen mobilizes stem/progenitor cells because it increases synthesis of a molecule called nitric oxide in the bone marrow. This synthesis is thought to trigger enzymes that mediate stem/progenitor cell release.”

Hopefully, future study of hyperbaric oxygen’s role in mobilizing stem cells will provide a wide array of treatments for combating injury and disease.

###

This article is available on the web at: http://ajpheart.physiology.org/cgi/reprint/00888.2005

PENN Medicine is a $2.7 billion enterprise dedicated to the related missions of medical education, biomedical research, and high-quality patient care. PENN Medicine consists of the University of Pennsylvania School of Medicine (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System.

Penn’s School of Medicine is ranked #2 in the nation for receipt of NIH research funds; and ranked #4 in the nation in U.S. News & World Report’s most recent ranking of top research-oriented medical schools. Supporting 1,400 fulltime faculty and 700 students, the School of Medicine is recognized worldwide for its superior education and training of the next generation of physician-scientists and leaders of academic medicine.

Penn Health System comprises: its flagship hospital, the Hospital of the University of Pennsylvania, consistently rated one of the nation’s “Honor Roll” hospitals by U.S. News & World Report; Pennsylvania Hospital, the nation’s first hospital; Presbyterian Medical Center; a faculty practice plan; a primary-care provider network; two multispecialty satellite facilities; and home health care and hospice.

http://www.eurekalert.org/pub_releases/2005-12/uops-psf122805.php